Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

The researchers suggest clinicians might tailor their approach to account for Asian Americans' younger average age when they ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Columnist Desiree Lama shares what she wishes she'd been told after her diagnosis of multiple sclerosis at age 17.

Non-drug therapy costs for people with MS in Austria can be high, averaging €136 per month, according to a study.

A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Pain is challenging, but it doesn't have to define your life. Episode 2 of Get Tough on Multiple Sclerosis offers practical ...

Quantum is partnering with Massachusetts General Hospital on a clinical study to test a PET tracer for monitoring response to ...

MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...